Oxidative Damage and Antioxidative Therapy in Systemic Sclerosis

Systemic sclerosis (SSc) is an autoimmune connective tissue disorder of unknown etiology. This disease is characterized by a large variety of clinical patterns, which include the fibrosis of skin and visceral organs causing a variety of clinical manifestations. Genetic and environmental factors participate in the etiology of this disease; however, recently many studies underline the oxidative background influencing the course and complications of this disease. Reactive oxygen species (ROS) synthesized in SSc can mediate extra- and intracellular oxidative processes affecting endothelial cells and fibroblasts. The estimation of prooxidative markers in the pathogenesis of SSc can enable the identification of useful markers for disease activity and, thus, may help in planning appropriate therapy focusing on the fibrotic or vascular pattern. Recently, many attempts have been made to find antioxidative molecules (nutritional and pharmacological) reducing the prooxidant state in a variety of cells—mainly in endothelium and proliferating fibroblasts. This paper presents both the background of oxidative stress processes in systemic sclerosis mediated by different mechanisms and the evidence suggesting which of the dietary and pharmacological antioxidants can be used as therapeutic targets for this disease.

• Publication year

  2014

• Venue

  Mediators of Inflammation

• Publication date

  2014-09-08

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1155/2014/389582PMID 25313270PMCID 4172878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression.

  2014cited by this paper
• Meta‐Analysis of Healing and Prevention of Digital Ulcers in Systemic Sclerosis

  2013cited by this paper
• Matrix Metalloproteinases: Inflammatory Regulators of Cell Behaviors in Vascular Formation and Remodeling

  2013cited by this paper
• TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities.

  2013cited by this paper
• Impaired α-TTP-PIPs Interaction Underlies Familial Vitamin E Deficiency

  2013cited by this paper
• Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases.

  2012cited by this paper
• High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients

  2012cited by this paper
• Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts.

  2012influential reference
• The organotelluride catalyst (PHTE)₂NQ prevents HOCl-induced systemic sclerosis in mouse.

  2012cited by this paper
• Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants

  2011influential reference
• Heme Oxygenase-1 Couples Activation of Mitochondrial Biogenesis to Anti-inflammatory Cytokine Expression*

  2011cited by this paper
• Promotion of plasma membrane repair by vitamin E

  2011cited by this paper
• The organotelluride catalyst LAB027 prevents colon cancer growth in the mice

  2011cited by this paper
• Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis

  2011cited by this paper
• Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model.

  2010cited by this paper
• Reactive species and DNA damage in chronic inflammation: reconciling chemical mechanisms and biological fates

  2010cited by this paper
• MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.

  2010cited by this paper
• Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.

  2010cited by this paper
• Exercise in systemic sclerosis intensifies systemic inflammation and oxidative stress

  2010cited by this paper
• Reactive oxygen species in TNFα-induced signaling and cell death

  2010cited by this paper
• The treatment with N-acetylcysteine of Raynaud’s phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients

  2009cited by this paper
• Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis.

  2009cited by this paper
• Scleroderma.

  2009cited by this paper
• Selective Oxidation of DNA Topoisomerase 1 Induces Systemic Sclerosis in the Mouse1

  2009cited by this paper
• Circulating Tissue Inhibitor of Matrix Metalloproteinase-4 (TIMP-4) in Systemic Sclerosis Patients with Elevated Pulmonary Arterial Pressure

  2009cited by this paper
• (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R.

  2009cited by this paper
• Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon.

  2008cited by this paper
• The Office of Dietary Supplements

  2008cited by this paper
• Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure.

  2008cited by this paper
• Systemic sclerosis: a prototypic multisystem fibrotic disorder.

  2007cited by this paper
• Inhibition of NADPH oxidase subunits translocation by tea catechin EGCG in mast cell.

  2007cited by this paper
• The levels of lycopene, alpha-tocopherol and a marker of oxidative stress in healthy northeast Thai elderly.

  2007cited by this paper
• Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis

  2007influential reference
• Increased serum levels of nitrotyrosine, a marker for peroxynitrite production, in systemic sclerosis.

  2007cited by this paper
• Green tea polyphenols as an anti-oxidant and anti-inflammatory agent for cardiovascular protection.

  2007cited by this paper
• Nitric oxide mediates NADPH oxidase function via heme oxygenase-1 in human endothelial cells

  2006cited by this paper
• The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?

  2006cited by this paper
• NO Modulates NADPH Oxidase Function Via Heme Oxygenase-1 in Human Endothelial Cells

  2006cited by this paper
• Mechanisms and consequences of fibrosis in systemic sclerosis

  2006cited by this paper
• Antioxidants Relieve Phosphatase Inhibition and Reduce PDGF Signaling in Cultured VSMCs and in Restenosis

  2006cited by this paper
• Rate dependency and role of nitric oxide in the vascular response to direct cooling in human skin.

  2006cited by this paper
• Matrix Metalloproteinase-9 and Autoimmune Diseases

  2006cited by this paper
• Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules.

  2006cited by this paper
• Intracellular signaling network as a prime chemopreventive target of (-)-epigallocatechin gallate.

  2006cited by this paper
• Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.

  2006cited by this paper
• Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

  2006cited by this paper
• Platelet-derived Growth Factor and Reactive Oxygen Species (ROS) Regulate Ras Protein Levels in Primary Human Fibroblasts via ERK1/2

  2005cited by this paper
• The basics about nitric oxide.

  2005cited by this paper
• Mechanisms of Raynaud’s disease

  2005cited by this paper
• Significant Changes of Peripheral Perfusion and Plasma Adrenomedullin Levels in N-Acetylcysteine Long Term Treatment of Patients with Sclerodermic Raynaud's Phenomenon

  2005cited by this paper
• Gene expression profiling of NRF2-mediated protection against oxidative injury.

  2005influential reference
• Controlling tumor growth by modulating endogenous production of reactive oxygen species.

  2005cited by this paper
• Antibodies against Human Cytomegalovirus in the Pathogenesis of Systemic Sclerosis: A Gene Array Approach

  2005cited by this paper
• Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement.

  2005cited by this paper
• High-dose acetylcysteine in idiopathic pulmonary fibrosis.

  2005cited by this paper
• Sympathetic, sensory, and nonneuronal contributions to the cutaneous vasoconstrictor response to local cooling.

  2005cited by this paper
• Differential modulation of normal and tumor cell proliferation by reactive oxygen species.

  2005cited by this paper
• Pathogenesis of Raynaud's phenomenon.

  2005cited by this paper
• Interleukin-13 Stimulates the Transcription of the Human α2(I) Collagen Gene in Human Dermal Fibroblasts*

  2004cited by this paper
• The transcription factor NRF2 protects against pulmonary fibrosis

  2004cited by this paper
• IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients.

  2004cited by this paper
• Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.

  2003cited by this paper
• Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis.

  2003cited by this paper
• Ginkgo biloba extract inhibits tumor necrosis factor-alpha-induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells.

  2003cited by this paper
• Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.

  2003cited by this paper
• Ginkgo biloba Extract Inhibits Tumor Necrosis Factor-&agr;–Induced Reactive Oxygen Species Generation, Transcription Factor Activation, and Cell Adhesion Molecule Expression in Human Aortic Endothelial Cells

  2003cited by this paper
• Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features

  2003influential reference
• New insights into the pathogenesis of systemic sclerosis.

  2003cited by this paper
• Ginkgo biloba Extract Inhibits Tumor Necrosis Factor-α–Induced Reactive Oxygen Species Generation, Transcription Factor Activation, and Cell Adhesion Molecule Expression in Human Aortic Endothelial Cells

  2003cited by this paper
• Effect of N-acetyl-L-cysteine on peroxynitrite and superoxide anion production of lung alveolar macrophages in systemic sclerosis.

  2002cited by this paper
• Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough.

  2002cited by this paper
• Beauty and the beast. The nitric oxide paradox in systemic sclerosis.

  2002cited by this paper
• Genetic epidemiology: Systemic sclerosis

  2002cited by this paper
• Inhibition of NADH/NADPH oxidase affects signal transduction by growth factor receptors in normal fibroblasts.

  2002influential reference
• The role of protein nitration in the inhibition of platelet activation by peroxynitrite

  2002influential reference
• The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo-controlled trial

  2002cited by this paper
• Vitamin E: action, metabolism and perspectives

  2001cited by this paper
• Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA.

  2001cited by this paper
• Nitric oxide and the regulation of gene expression.

  2001cited by this paper
• Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.

  2001cited by this paper
• The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis.

  2001cited by this paper
• Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway.

  2001influential reference
• Vitamin E: action, metabolism and perspectives.

  2001cited by this paper
• A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis.

  2000cited by this paper
• Severe organ involvement in systemic sclerosis with diffuse scleroderma.

  2000cited by this paper
• Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis.

  2000cited by this paper
• Increased nitric oxide production in patients with systemic sclerosis.

  2000cited by this paper
• Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury.

  2000cited by this paper
• Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis

  2000cited by this paper
• Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1.

  2000cited by this paper
• Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis.

  2000cited by this paper
• Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans.

  1999cited by this paper
• Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma.

  1999cited by this paper
• Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.

  1999cited by this paper
• 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases.

  1998cited by this paper
• Ascorbic acid absorption in patients with systemic sclerosis.

  1997cited by this paper
• Advanced oxidation protein products as a novel marker of oxidative stress in uremia.

  1996cited by this paper
• Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma.

  1996cited by this paper
• Vitamin E potentiates arachidonate release and phospholipase A2 activity in rat heart myoblastic cells.

  1996cited by this paper
• Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis.

  1996cited by this paper

• Effects of Huoxue Chubi decoction on protein kinase B-mammalian target of rapamycin autophagy pathway in scleroderma Balb/c model mice.

  2025cites this paper
• Identification of crosstalk genes and diagnostic biomarkers in systemic sclerosis associated sarcopenia through integrative analysis and machine learning

  2025cites this paper
• The Relationship Between Microbiota, Nutrition, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis: A Systematic Review of the Literature

  2025cites this paper
• Nanofat and lipofilling for cutaneous fibrosis in scleroderma: Current evidence and future directions

  2025cites this paper
• Evaluation of Thiol Disulfide, Ischemia Modified Albumin, and Prolidase Parameters in Patients with Localized Scleroderma

  2024cites this paper
• Differential gene expression in Clostridium perfringens during pre-and post-infection phases and in jejunal tissues of broilers with necrotic enteritis induced by Clostridium perfringens alone and its coinfection with Eimeria

  2024cites this paper
• A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study

  2024cites this paper
• The effects of supplementation of vitamin D to the egg‐yolk extender on cryopreservation of ram semen

  2024cites this paper
• Increased oxidative stress response in circulating blood of systemic sclerosis patients - relation to disease characteristics and inflammatory blood biomarkers.

  2023cites this paper
• Effects of upadacitinib and PD29 on oxidative damage and inflammation in bleomycin-induced scleroderma model kidney tissues

  2023cites this paper
• Redox Imbalance in Neurological Disorders in Adults and Children

  2023cites this paper
• Sodium Butyrate as Adjuvant Therapy with Mycophenolate Mofetil for Amelioration of Skin Fibrosis in Bleomycin-induced Scleroderma in Mice via Immunomodulatory, Antioxidant, Antiapoptotic and Antifibrotic Mechanisms

  2022cites this paper
• Oxidative stress in Hashimoto’s thyroiditis: possible adjuvant therapies to attenuate deleterious effects

  2022cites this paper
• Systemic sclerosis in adults. Part II: Management and therapeutics.

  2022cites this paper
• Inhibition of skin fibrosis in systemic sclerosis by botulinum toxin B via the suppression of oxidative stress

  2021cites this paper
• Pathophysiology of systemic sclerosis.

  2021cites this paper
• Oxidative Stress Induced by Reactive Oxygen Species (ROS) and NADPH Oxidase 4 (NOX4) in the Pathogenesis of the Fibrotic Process in Systemic Sclerosis: A Promising Therapeutic Target

  2021cites this paper
• Linagliptin ameliorates pulmonary fibrosis in systemic sclerosis mouse model via inhibition of endothelial-to-mesenchymal transition

  2021cites this paper
• Iloprost Attenuates Oxidative Stress-Dependent Activation of Collagen Synthesis Induced by Sera from Scleroderma Patients in Human Pulmonary Microvascular Endothelial Cells

  2021cites this paper
• Current evidence to support the therapeutic potential of flavonoids in oxidative stress-related dermatoses

  2021cites this paper
• XII ISIN Conference on Immunonutrition Barcelona 2021

  2021cites this paper
• Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment

  2021cites this paper
• Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development

  2021cites this paper
• The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: from Origin to Therapeutic Targeting.

  2021cites this paper
• Quantification of mitochondrial DNA damage and copy number in circulating blood of patients with systemic sclerosis by a qPCR-based assay☆☆☆

  2020cites this paper
• Redox distress in organ fibrosis: The role of noncoding RNAs

  2020cites this paper
• The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species

  2020cites this paper
• Quantificação do dano ao DNA mitocondrial e número de cópias no sangue circulante de pacientes com esclerose sistêmica em um ensaio baseado em qPCR

  2020cites this paper
• Targeting Oxidative Stress, Transforming Growth Factor Beta-1, and the Mammalian Target of Rapamycin by Valproic Acid to Ameliorate Bleomycin-Induced Scleroderma

  2020cites this paper
• Liver damage in bleomycin-induced pulmonary fibrosis in mice

  2019cites this paper
• A Double-blind, Randomized Controlled Trial of Ciplukan (Physalis angulata Linn) Extract on Skin Fibrosis, Inflammatory, Immunology, and Fibrosis Biomarkers in Scleroderma Patients.

  2019cites this paper
• Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma?

  2019cites this paper
• Implication of oxidative stress in the pathogenesis of systemic sclerosis via inflammation, autoimmunity and fibrosis

  2019cites this paper
• Emerging Roles of Redox-Mediated Angiogenesis and Oxidative Stress in Dermatoses

  2019cites this paper
• Scleroderma: An insight into causes, pathogenesis and treatment strategies.

  2019cites this paper
• Oxidative stress in the pathogenesis of systemic scleroderma: An overview

  2018cites this paper
• Withaferin A attenuates bleomycin‐induced scleroderma by targeting FoxO3a and NF‐&kgr;&bgr; signaling: Connecting fibrosis and inflammation

  2018cites this paper
• A Potential Link Between Oxidative Stress and Endothelial-to-Mesenchymal Transition in Systemic Sclerosis

  2018influential citation
• The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy

  2018cites this paper
• The Nrf2-Antioxidant Response Element Signaling Pathway Controls Fibrosis and Autoimmunity in Scleroderma

  2018cites this paper
• The clinical effects of l‐arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon

  2018cites this paper
• Expression of the oxygen-sensitive transcription factor subunit HIF-1α in patients suffering from secondary Raynaud syndrome

  2018cites this paper
• NADPH oxidase, oxidative stress and fibrosis in systemic sclerosis

  2018cites this paper
• PPARgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders

  2018cites this paper
• Myeloid related proteins are up‐regulated in autoimmune thyroid diseases and activate toll‐like receptor 4 and pro‐inflammatory cytokines in vitro

  2018cites this paper
• Scleroderma Defiance: A Practical, Educational and Free Guide for Self-Management of Scleroderma

  2018cites this paper
• Proteomic Investigation of Dermal Fibroblasts Isolated from Affected and Unaffected Skin Samples from Patients with Limited Cutaneous Systemic Sclerosis: 2 Distinct Entities?

  2017cites this paper
• Therapeutic potential of NADPH oxidase 1/4 inhibitors

  2017cites this paper
• The Journal of Rheumatology Sclerosis : 2 Distinct Entities ? Unaffected Skin Samples from Patients with Limited Cutaneous Systemic Proteomic Investigation of Dermal Fibroblasts Isolated from Affected and

  2016cites this paper
• A neoteric multidrug combination: novel approach to limited cutaneous systemic scleroderma involving the face

  2016cites this paper
• RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis

  2016cites this paper
• Oxidative Stress and Advanced Glycation End Products in Hashimoto's Thyroiditis

  2016cites this paper
• The relationship between oxidative stress and autoimmunity in Hashimoto's thyroiditis.

  2015cites this paper
• Increased Expression of NAPDH Oxidase 4 in Systemic Sclerosis Dermal Fibroblasts: Regulation by Transforming Growth Factor β

  2015cites this paper
• Université de Montréal-Thèse numérique

  2014cites this paper